FADS2 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SC 26196 | 218136-59-5 | sc-361350 sc-361350A | 10 mg 50 mg | $158.00 $630.00 | 3 | |
SC 26196 acts as a selective modulator of fatty acid desaturase 2 (FADS2), influencing lipid metabolism through its unique interactions with the enzyme's active site. This compound exhibits a distinct mechanism of action, enhancing the conversion of saturated fatty acids to unsaturated forms. Its kinetic profile reveals a competitive inhibition pattern, allowing for precise regulation of desaturation pathways. The compound's structural features facilitate specific binding, impacting overall lipid composition and cellular signaling. | ||||||
CP 24,879 (hydrochloride) | 10141-51-2 | sc-205269 sc-205269A sc-205269B sc-205269C | 1 mg 5 mg 10 mg 50 mg | $39.00 $171.00 $300.00 $1321.00 | 1 | |
CP 24,879 (hydrochloride) serves as a potent modulator of fatty acid desaturase 2 (FADS2), engaging in unique molecular interactions that alter lipid biosynthesis. Its distinct binding affinity promotes the transformation of saturated fatty acids, influencing metabolic pathways. The compound exhibits a non-competitive inhibition mechanism, allowing it to fine-tune desaturation rates. Additionally, its physicochemical properties enhance solubility, optimizing its interaction with lipid membranes and cellular components. | ||||||
Conjugated Linoleic Acid (9Z,11E) | 2540-56-9 | sc-205264 sc-205264A sc-205264B sc-205264C sc-205264D | 10 mg 50 mg 100 mg 1 g 10 g | $149.00 $577.00 $1007.00 $3751.00 $27056.00 | ||
Conjugated Linoleic Acid (9Z,11E) acts as a selective modulator of fatty acid desaturase 2 (FADS2), facilitating unique enzymatic pathways that influence lipid metabolism. Its structural conformation allows for specific interactions with the active site of FADS2, promoting the conversion of fatty acids through a competitive inhibition mechanism. This compound's unique stereochemistry enhances its affinity for lipid bilayers, impacting membrane fluidity and cellular signaling processes. | ||||||
CAY 10566 | 944808-88-2 | sc-205109 sc-205109A sc-205109B | 1 mg 5 mg 25 mg | $117.00 $512.00 $1527.00 | 4 | |
CAY10566 is a small molecule FADS2 inhibitor that interferes with the desaturation process of fatty acids. It directly binds to FADS2, disrupting its enzymatic activity in the conversion of fatty acids. This direct inhibition alters the fatty acid profile by limiting the formation of more unsaturated fatty acids, impacting cellular lipid metabolism and signaling. | ||||||
δ-Tocotrienol | 25612-59-3 | sc-205547 sc-205547A | 1 mg 5 mg | $49.00 $203.00 | 1 | |
δ-Tocotrienol is a natural compound that indirectly modulates FADS2 by influencing the expression of the enzyme. It downregulates the transcriptional activity of SREBP-1c, a key regulator of lipid metabolism, leading to decreased FADS2 expression. | ||||||
BRD 7389 | 376382-11-5 | sc-361129 sc-361129A | 10 mg 50 mg | $181.00 $714.00 | ||
BRD7389 is a chemical compound that indirectly influences FADS2 by targeting the sterol regulatory element-binding proteins (SREBPs). It inhibits the processing of SREBPs, leading to decreased transcriptional activation of FADS2. This indirect modulation impacts fatty acid desaturation, altering the cellular lipid composition and potentially affecting signaling pathways reliant on specific fatty acids. | ||||||
FABP4 Inhibitor | 300657-03-8 | sc-202606 | 5 mg | $208.00 | 2 | |
FABP4 Inhibitor (BMS-309403) is a chemical compound that indirectly influences FADS2 by targeting the sterol regulatory element-binding proteins (SREBPs). It inhibits the processing of SREBPs, leading to decreased transcriptional activation of FADS2. This indirect modulation affects fatty acid desaturation, altering the cellular lipid composition and potentially impacting signaling cascades dependent on specific fatty acids. | ||||||